WO2018081625A3 - Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques - Google Patents

Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques Download PDF

Info

Publication number
WO2018081625A3
WO2018081625A3 PCT/US2017/058855 US2017058855W WO2018081625A3 WO 2018081625 A3 WO2018081625 A3 WO 2018081625A3 US 2017058855 W US2017058855 W US 2017058855W WO 2018081625 A3 WO2018081625 A3 WO 2018081625A3
Authority
WO
WIPO (PCT)
Prior art keywords
specific
blood samples
cancer therapies
digital analysis
determine efficacy
Prior art date
Application number
PCT/US2017/058855
Other languages
English (en)
Other versions
WO2018081625A2 (fr
Inventor
Daniel Haber
Shyamala Maheswaran
Tanya TODOROVA
Mark KALINICH
David Tomoaki MIYAMOTO
Xin Hong
Original Assignee
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation filed Critical The General Hospital Corporation
Priority to JP2019522657A priority Critical patent/JP7195252B2/ja
Priority to EP17865612.0A priority patent/EP3532642B1/fr
Priority to US16/344,557 priority patent/US11371101B2/en
Priority to EP21212237.8A priority patent/EP3985127A1/fr
Priority to CN201780075515.XA priority patent/CN110050075B/zh
Publication of WO2018081625A2 publication Critical patent/WO2018081625A2/fr
Publication of WO2018081625A3 publication Critical patent/WO2018081625A3/fr
Priority to US17/826,834 priority patent/US20220364185A1/en
Priority to JP2022142901A priority patent/JP7441907B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne de nouveaux procédés de dosage pour l'analyse d'ARN, par exemple, issu de cellules tumorales circulantes (CTC), d'exosomes spécifiques à la tumeur ou d'ARN acellulaire spécifique à la tumeur, dans un échantillon de sang du sujet pour déterminer un niveau d'expression d'un ou de plusieurs marqueurs de lignée dans l'échantillon de sang, le niveau d'expression d'un ou de plusieurs marqueurs de lignée spécifique étant prédictif de la survie sans progression et de la survie globale pour un régime de traitement anticancéreux spécifique chez ce sujet.
PCT/US2017/058855 2016-10-27 2017-10-27 Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques WO2018081625A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2019522657A JP7195252B2 (ja) 2016-10-27 2017-10-27 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析
EP17865612.0A EP3532642B1 (fr) 2016-10-27 2017-10-27 Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques
US16/344,557 US11371101B2 (en) 2016-10-27 2017-10-27 Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
EP21212237.8A EP3985127A1 (fr) 2016-10-27 2017-10-27 Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques
CN201780075515.XA CN110050075B (zh) 2016-10-27 2017-10-27 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析
US17/826,834 US20220364185A1 (en) 2016-10-27 2022-05-27 Digital Analysis of Blood Samples to Determine Efficacy of Cancer Therapies for Specific Cancers
JP2022142901A JP7441907B2 (ja) 2016-10-27 2022-09-08 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413952P 2016-10-27 2016-10-27
US62/413,952 2016-10-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/344,557 A-371-Of-International US11371101B2 (en) 2016-10-27 2017-10-27 Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
US17/826,834 Division US20220364185A1 (en) 2016-10-27 2022-05-27 Digital Analysis of Blood Samples to Determine Efficacy of Cancer Therapies for Specific Cancers

Publications (2)

Publication Number Publication Date
WO2018081625A2 WO2018081625A2 (fr) 2018-05-03
WO2018081625A3 true WO2018081625A3 (fr) 2018-06-07

Family

ID=62025512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/058855 WO2018081625A2 (fr) 2016-10-27 2017-10-27 Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques

Country Status (5)

Country Link
US (2) US11371101B2 (fr)
EP (2) EP3532642B1 (fr)
JP (2) JP7195252B2 (fr)
CN (1) CN110050075B (fr)
WO (1) WO2018081625A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3274476B1 (fr) 2015-03-25 2023-06-07 The General Hospital Corporation Analyse numérique de cellules tumorales circulantes dans des échantillons de sang
EP3532642B1 (fr) * 2016-10-27 2021-12-08 The General Hospital Corporation Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques
WO2020006098A2 (fr) * 2018-06-26 2020-01-02 Children's National Medical Center Marqueurs associés à une tumeur pour la détection d'une maladie résiduelle minimale à l'aide d'une pcr numérique à gouttelettes
WO2020102506A1 (fr) * 2018-11-14 2020-05-22 The Broad Institute, Inc. Composés activateurs du récepteur d'aryl hydrocarbone (ahr) en tant qu'agents thérapeutiques contre le cancer
TWI790399B (zh) * 2019-08-30 2023-01-21 長庚大學 循環腫瘤細胞資訊評估方法及其分析方法
CN112698033A (zh) * 2020-12-09 2021-04-23 复旦大学附属中山医院 一种血源性外泌体her2的检测方法及其应用
CN113292643A (zh) * 2021-05-31 2021-08-24 南京市第二医院 一种肝癌肿瘤标志物及其应用
CN114395622A (zh) * 2021-12-13 2022-04-26 深圳先进技术研究院 一种利用数字pcr检测循环肿瘤细胞egfr基因突变的方法及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150168413A1 (en) * 2012-07-02 2015-06-18 The General Hospital Corporation Diagnosis and monitoring treatment of prostrate cancer
US20150233927A1 (en) * 2012-09-19 2015-08-20 Cornell University Identifying taxane sensitivity in prostate cancer patients
US20150240314A1 (en) * 2012-09-14 2015-08-27 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
US20150301055A1 (en) * 2010-08-18 2015-10-22 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
WO2016154600A1 (fr) * 2015-03-25 2016-09-29 The General Hospital Corporation Analyse numérique de cellules tumorales circulantes dans des échantillons de sang

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US889A (en) 1838-08-20 Mode of constructing metal bench-vises
US8535A (en) 1851-11-18 Stove-geate
DE29623597U1 (de) 1996-11-08 1999-01-07 Eppendorf Geraetebau Netheler Temperierblock mit Temperiereinrichtungen
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
CA2311201A1 (fr) 1999-08-05 2001-02-05 Genset S.A. Sequences marqueurs exprimees et proteines humaines codees
EP1353947A2 (fr) 2000-12-08 2003-10-22 Ipsogen Caracterisation de l'expression genique des carcinomes primaires du sein a l'aide de reseaux de genes d'interet
CA2443627A1 (fr) * 2001-05-16 2002-11-21 Novartis Ag Genes exprimes dans le cancer du sein en tant que cibles therapeutique et de pronostic
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20070026417A1 (en) 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20090118175A1 (en) * 2005-05-06 2009-05-07 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer
EP2079838A1 (fr) 2006-05-16 2009-07-22 NuGEN Technologies, Inc. Procédé de séparation et de purification d'acides nucléiques reposant sur des interactions de charges réversibles
WO2009051734A1 (fr) 2007-10-17 2009-04-23 The General Hospital Corporation Dispositifs à base de micropuce pour capturer des cellules tumorales circulantes et procédés pour leur utilisation
US9068181B2 (en) 2008-05-23 2015-06-30 The General Hospital Corporation Microfluidic droplet encapsulation
US20120252015A1 (en) 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
US9625454B2 (en) 2009-09-04 2017-04-18 The Research Foundation For The State University Of New York Rapid and continuous analyte processing in droplet microfluidic devices
WO2011100604A2 (fr) 2010-02-12 2011-08-18 Raindance Technologies, Inc. Analyse numérique d'analytes
US20120329061A1 (en) 2010-03-11 2012-12-27 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of cancer patients
AU2015268617A1 (en) * 2010-03-31 2016-01-07 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
PL2553118T3 (pl) * 2010-03-31 2015-03-31 Sividon Diagnostics Gmbh Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznego
US20140141986A1 (en) * 2011-02-22 2014-05-22 David Spetzler Circulating biomarkers
WO2012135397A2 (fr) * 2011-03-29 2012-10-04 Lisanti Michael P Signatures géniques induites par le lactate et des cétones et leur utilisation pour le diagnostic d'une maladie et la prédiction d'un devenir clinique
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
JP6247218B2 (ja) 2011-10-24 2017-12-13 ザ ジェネラル ホスピタル コーポレイション 癌のバイオマーカー
AU2013302867A1 (en) 2012-08-13 2015-02-26 The Regents Of The University Of California Methods and systems for detecting biological components
WO2014075067A1 (fr) * 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Méthodes permettant de prédire l'issue du cancer du sein
WO2014165762A1 (fr) 2013-04-05 2014-10-09 Raindance Technologies, Inc. Analyse de cellules rares après sélection négative
BR112016002970A2 (pt) * 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
US10202577B2 (en) 2013-10-18 2019-02-12 The General Hospital Corporation Microfluidic sorting using high gradient magnetic fields
EP3116496A1 (fr) * 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes
CN106456776A (zh) * 2014-05-21 2017-02-22 豪夫迈·罗氏有限公司 用PI3K抑制剂Pictilisib治疗PR阳性腔性A乳腺癌的方法
JP6782698B2 (ja) * 2014-12-12 2020-11-11 セルキュイティー インコーポレイテッド がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法
US20180057899A1 (en) 2015-02-20 2018-03-01 Comelz S.P.A. Method for cutting natural hides and the like
DK3268493T3 (da) * 2015-03-12 2022-03-07 Janssen Pharmaceutica Nv Fuldblodsbaserede mrna-markører til forudsigelse af prostatakræft og fremgangsmåder til detektering deraf
EP3532642B1 (fr) * 2016-10-27 2021-12-08 The General Hospital Corporation Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150301055A1 (en) * 2010-08-18 2015-10-22 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
US20150168413A1 (en) * 2012-07-02 2015-06-18 The General Hospital Corporation Diagnosis and monitoring treatment of prostrate cancer
US20150240314A1 (en) * 2012-09-14 2015-08-27 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
US20150233927A1 (en) * 2012-09-19 2015-08-20 Cornell University Identifying taxane sensitivity in prostate cancer patients
WO2016154600A1 (fr) * 2015-03-25 2016-09-29 The General Hospital Corporation Analyse numérique de cellules tumorales circulantes dans des échantillons de sang

Also Published As

Publication number Publication date
JP2020501517A (ja) 2020-01-23
EP3532642A2 (fr) 2019-09-04
EP3985127A1 (fr) 2022-04-20
EP3532642B1 (fr) 2021-12-08
US11371101B2 (en) 2022-06-28
JP7441907B2 (ja) 2024-03-01
US20220364185A1 (en) 2022-11-17
JP2022184902A (ja) 2022-12-13
CN110050075B (zh) 2024-04-02
JP7195252B2 (ja) 2022-12-23
US20190391134A1 (en) 2019-12-26
CN110050075A (zh) 2019-07-23
EP3532642A4 (fr) 2020-06-24
WO2018081625A2 (fr) 2018-05-03

Similar Documents

Publication Publication Date Title
WO2018081625A3 (fr) Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques
MX2021006510A (es) Nanomotores impulsados por enzimas funcionalizados.
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
WO2016138105A3 (fr) Dosages pour déterminer la méthylation de l'adn et marqueurs de méthylation de l'adn du cancer
WO2015052583A3 (fr) Méthode de pronostic et de traitement d'une métastase cancéreuse
EP3274476A4 (fr) Analyse numérique de cellules tumorales circulantes dans des échantillons de sang
EP3683321A3 (fr) Procédés relatifs à des groupes de cellules tumorales circulantes et au traitement du cancer
WO2019079624A3 (fr) Msi à partir de biopsies de liquide
EP3159695A3 (fr) Procédé de diagnostic du cancer du pancréas
Bevilacqua et al. A “live” biopsy in a small-cell lung cancer patient by detection of circulating tumor cells
EA201691352A1 (ru) Диагностика рака легкого с помощью циркулирующих опухолевых клеток
CA2888908A1 (fr) Anticorps contre l'antigene 1 associe aux reins et leurs fragments de liaison a l'antigene
EA201691682A1 (ru) Способы анализирования редких циркулирующих в крови клеток
IL270974A (en) Methods for determining therapies based on single cell characterization of circulating cancer cells (CTC) in metastatic disease
WO2015153997A3 (fr) Anticorps anti-notch 3 et leurs utilisations
WO2016201365A3 (fr) Procédés pour le traitement de cancers
WO2016198833A3 (fr) Procédés
WO2011145085A3 (fr) Nouveaux anticorps et procédés d'utilisation pour le traitement et le diagnostic du cancer
WO2014151079A8 (fr) Biomarqueurs basés sur le rapport et leur procédés d'utilisation
MX2017005650A (es) Composicion de antigeno para detectar enfermedad de chagas.
Anitha et al. Circulating tumor cells in oral squamous cell carcinoma-an enigma or reality?
WO2015193738A3 (fr) Procédés et biomarqueurs pour l'analyse du cancer colorectal
Augustine et al. Circulating tumor cells in oral cancer
Kujawa et al. STROMAL FIBRONECTIN AND PERIOSTIN EXPRESSION ARE CORRELATED WITH OVERALL SURVIVAL OF OVARIAN CANCER PATIENTS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17865612

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019522657

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017865612

Country of ref document: EP

Effective date: 20190527